このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Pulse Biosciences マネジメント

マネジメント基準チェック /24

Pulse Biosciences'の CEO はBurke Barrettで、 May2024年に任命され、の在任期間は 1 年未満です。は、会社の株式の0.018%を直接所有しており、その価値は€ 110.37K 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と6.6年です。

主要情報

Burke Barrett

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.02%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	6.6yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Burke Barrett (60 yo)

less than a year

在職期間

Mr. Burke T. Barrett is President & CEO of Pulse Biosciences, Inc. from May 14, 2024 and also serves as its Director since May 2024. Mr. Barrett served as President, Secretary and Director of CardioFocus,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Duggan	Executive Chairman	6.6yrs	US$257.41k	67.86% $ 397.6m
Darrin Uecker	CTO & Director	1.8yrs	US$5.39m	0.27% $ 1.6m
Mitchell Levinson	Chief Strategy Officer	2.8yrs	US$1.69m	0.18% $ 1.1m
Kevin Danahy	Chief Commercial Officer	less than a year	US$5.86m	0.065% $ 380.7k
Burke Barrett	President	less than a year	データなし	0.018% $ 106.1k
Edison Manuel	Vice President of Operations	7.2yrs	データなし	データなし
Richard Nuccitelli	Chief Science Officer	9.6yrs	データなし	データなし
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.1yrs	データなし	データなし
Patty Perla	Vice President of Human Resources	4.4yrs	データなし	データなし
David Danitz	Senior Vice President of Engineering	2.8yrs	データなし	データなし
Gansevoort Dunnington	Chief Medical Officer	1.1yrs	データなし	データなし
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	データなし	データなし

2.3yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: 6L8の経営陣は経験豊富であると考えられます ( 2.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Duggan	Executive Chairman	6.6yrs	US$257.41k	67.86% $ 397.6m
Darrin Uecker	CTO & Director	8.8yrs	US$5.39m	0.27% $ 1.6m
Burke Barrett	President	less than a year	データなし	0.018% $ 106.1k
Richard van den Broek	Independent Director	3.8yrs	US$208.89k	0% $ 0
Mahkam Zanganeh	Independent Director	7.3yrs	US$173.00k	1.36% $ 8.0m
Manmeet Soni	Lead Independent Director	6.6yrs	US$180.07k	0% $ 0

6.6yrs

平均在職期間

58yo

平均年齢

経験豊富なボード: 6L8の取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

Pulse Biosciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman recently bought €1.0m worth of stock

Chief Strategy Officer recently bought €97k worth of stock

Recent updates

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman recently bought €1.0m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought €97k worth of stock

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought €72k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Independent Chairman of the Board recently bought €42m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

New 90-day high: €23.60

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

New 90-day high: €19.30

New 90-day high: €15.20

Pulse Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery Virtual Annual Meeting

Pulse Biosciences, Inc. Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Pulse Biosciences, Inc. Announces the Company Is Not Reasonably Estimate the Future Impact to the Operations and Financial Results

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24